

## ASA SUPERGENERICS LIMITED

Corporate Office: Office No. 705, Minerva Estate, Asha Nagar A Wing, O2 Commercial Tower,

Mulund (West), Mumbai-400 080

Email: info@lasalabs.com • Website: www.lasalabs.com

Ref. No.: LASA/SE/20-21/41

#### Monday, February 01 2021

То,	To,		
Corporate Services Department	Corporate Services Department		
BSE Limited	National Stock Exchange of India Limited		
Phiroze Jeejeebhoy Towers,	"Exchange Plaza", Plot No. C/1,		
Dalal Street,	G Block Bandra-Kurla Complex,		
Mumbai – 400 001.	Bandra (E), Mumbai – 400 051.		
BSE CODE -540702	NSE CODE: LASA		

Dear Sir/Madam,

#### Sub. : Outcome of Board Meeting held today i.e. February 01, 2021

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today commenced at 10.30 a.m. and concluded at 12:30 p.m. have considered, approved and took on record the Unaudited Financial Results for the quarter ended December 31 2020.

A copy of the statement of Unaudited Financial Results along with Limited Review Report submitted by the Statutory Auditors of the Company is attached herewith.

The above information is also available on the company's website at <a href="www.lasalabs.com">www.lasalabs.com</a> and on the website of the stock Exchange at <a href="www.bseindia.com">www.bseindia.com</a> and <a href="www.nseindia.com">www.nseindia.com</a>.

Please take the above on your records.

THANKING YOU
YOURS SINCERELY
FOR LASA SUPERGENERICS LIMITED

**NIDHI KULSHRESHTHA** 

**COMPANY SECRETARY AND COMPLIANCE OFFICER** 



# ASA SUPERGENERICS LIMITED

Corporate Office: Office No 705, Minera Estate, A wing, O2 Commercial Tower,

Mulund (W) Mumbai - 400 080, Maharashtra, INDIA Email: info@lasalabs.com • Website: www.lasalabs.com

Statement of Unaudited Financial Results for Quarter and Nine months ended 31st Dec, 2020

(Rs. In Lakhs)

Particulars	Quarter ended			Nine Months Ended		Year ended
	31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	31.03.2020 (Audited)
1. INCOME	7.1	5 400 00	3,928.97	16,327.77	11,868.56	16,727.12
a. Revenue from Operations	5,398.71	5,469.09 0.32	2.58	24.97	15.85	23.15
b. Other Income	21.20			16,352.75	11,884.41	16,750.27
Total Income	5,419.92	5,469.41	3,931.54	10,332.73	11,004.41	10,7 50.27
2. Expenses		0 000 50	4 024 24	0.204.45	6,157.41	8,651.33
a. Cost of Materials consumed	2,601.21	3,009.52	1,931.24	8,324.45	49.41	49.41
b. Cost of Traded Goods	-	-	-	-	49.41	49.41
c. Change in Inventories of Finished Goods, Work-in-Progress and	295.15	51.16	245.85	909.75	1,026.91	764.51
Stock in trade	425.41	328.63	350.80	1,056.46	999.51	1,341.60
d. Employee benefits expenses	7.62	19.11	166.51	152.55	579.37	810.43
e. Finance costs	409.07	406.66	439.65	1,188.34	1,298.08	1,733.90
f. Depreciation & amortizations expenses	821.23	799.98	562.84	2,283.72	1,543.18	2,925.49
g. Other Expenses	4,559.68	4,615.06	3,696.89	13,915.27	11,653.87	16,276.66
Total Expenses (a to g)	4,555.00	4,010.00	-	10,010	-	
Exceptional Items	860.24	854.35	234.65	2,437.47	230.54	473.60
3. Profit / (Loss) before tax (1-2)	000.24	034.33	204.00	_,		1
4. Tax expense	64.71		42.54	64.71	42.54	90.79
Current Tax	139.96	149.25	(102.28)	565.58	46.42	(16.77
Deferred Tax	139.90	140.20	36.75	(90.79)		36.75
Short / Excess income tax provision for earlier years	655.56	705.10	257.65	1,897.98	104.83	
5. Net Profit / (Loss) after tax (3-4)	655.56	703.10	201.00	1,007.00	10 1100	1
6. Other Comprehensive Income						1
Items that will not be reclassified into Profit or Loss					1000	3.94
- Remeasurement of Defined Benefit Plans (Net of tax)	-	-	- 1		-	0.04
7. Total Comprehensive Income for the year (after tax) (5+6)	655.56	705.10	257.65	1,897.98	104.83	366.77
8. Paid-up Equity Share Capital (Face Value of Re. 10 /- each)	4,067.27	4,067.27	4,067.27	4,067.27	4,067.27	4,067.27
<ol> <li>Other Equity excluding Revaluation reserve as per Balance Sheet</li> </ol>					-	10,079.28
10. Earnings per Equity Share (of Rs. 10/- each)	1.61	1.73	0.89	4.67	0.42	1.26
(a) Basic			0.89	4.67	0.42	
(b) Diluted	1.61	1.73	0.89	4.07	0.42	1.20

### Notes:

- 1) The Above Financial Results were reviewed by the audit committee of the board on 1st February, 2021 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The auditors report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accoradance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.
- 2) The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segement information is not applicable.
- 3) The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgements and estimates, including in relation to recoverability of receivables, assessment of impairment of goodwill and intangibles, investments and inventory, based on the information available to date, while preparing the Company's financial results as of and for the period ended December 31, 2020. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
- 4) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

By order of the Board of Directors For Lasa Supergenerics Limited

Omkat Herlekar Chairman & Managing Director

(DIN No. 01587154) CIN: L24233MH2016PLC274202

Place: Mumbai

Date: 1st February, 2021



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors
LASA SUPERGENERICS LIMITED

- 1. We have reviewed the accompanying statement of unaudited financial results of LASA SUPERGENERICS LIMITED (the "Company") for the quarter and Nine Months ended December 31, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules Issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Thanawala & Company

Chartered Accountants

Firm Reg. No.: 110948W

CA Vijay Thanawala

Proprietor

Membership No.: 015632

Place: Mumbai

Date: 1st February 2020

UDIN: 21015632AAAABP7758

MUMBAI M.No.15632 Firm Reg. No.

110948W